This company listing is no longer active
ASLAN Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /06
ASLAN Pharmaceuticals has a total shareholder equity of $-18.0M and total debt of $26.5M, which brings its debt-to-equity ratio to -147.6%. Its total assets and total liabilities are $21.0M and $39.0M respectively.
主要情報
-147.6%
負債資本比率
US$26.52m
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$18.40m |
| エクイティ | -US$17.96m |
| 負債合計 | US$38.95m |
| 総資産 | US$20.99m |
財務状況分析
短期負債: ASLN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
長期負債: ASLN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
デット・ツー・エクイティの歴史と分析
負債レベル: ASLN has negative shareholder equity, which is a more serious situation than a high debt level.
負債の削減: ASLN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: ASLN has less than a year of cash runway based on its current free cash flow.
キャッシュランウェイの予測: ASLN has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.9% each year.